The new crown pneumonia vaccine is safe and effective for cancer patients

The new crown pneumonia vaccine is safe and effective for cancer patients

The new crown pneumonia vaccine is safe and effective for cancer patients The new crown pneumonia vaccine is safe and effective for cancer patients

Since the new crown pneumonia (COVID-19) pandemic, it is not clear what will happen to cancer patients undergoing treatment if they are infected with the new crown virus (SARS-CoV-2)
.

Related concerns are largely due to the impact of cancer and its treatment on the patient’s immune system

Cancer Cell

In a study of 200 confirmed cancer patients, researchers at Montefiore Health Center and Einstein College of Medicine found that after the vaccination was completed, 94% of patients showed seroconversion as a whole.
Determined by the presence of SARS-CoV-2 spike protein antibody
.

The response rate of solid tumor patients is very high, while the response rate of some blood cancer patients is low, but most of the latter also have an immune response

"Studies in the early stages of the pandemic found that the morbidity and mortality of cancer patients suffering from COVID-19 were higher than those of the general population
.

" Amit, the co-corresponding author of the paper, director of the Department of Hematology and Oncology of the Montefiore Health Center and Professor of Einstein College of Medicine Verma said, “We really need to work hard to protect these vulnerable patients from infection

"This study confirms that there is no need for patients to wait until they have completed chemotherapy or immunotherapy before being vaccinated
.

" said Balazs Halmos, co-corresponding author of the paper, director of the Multidisciplinary Thoracic Tumor Program at the Montefiore Health Center and professor at the Einstein School of Medicine "The side effects of vaccination seen in these populations are not more serious than those in other control groups

This study is the largest of its kind and aims to observe the seroconversion rate of cancer patients who have completed vaccination
.

Previous studies only focused on smaller samples, or only analyzed antibody levels after the first dose of the two-dose vaccine

In a serum test to detect immunoglobulin (IgG) levels after vaccination, the researchers found that 98% of patients with solid tumors showed seroconversion
.

Among patients with hematological tumors, the seroconversion rate is 85%

But patients receiving certain treatments are worse than others
.

The seroconversion rate of patients receiving blood cancer treatments that work by killing B cells (such as rituximab or CAR T therapy) is 70%

"Although those patients who received treatments that affected B cells performed poorly, the seropositivity of patients with
blood cancers that affected bone marrow cells rather than lymphocytes was quite good .

" Astha, the first author of the paper and a hematological tumor researcher at the Montefiore Health Center Thakkar said, "This includes people with acute myeloid leukemia and myelodysplastic syndromes

The researchers said that one of the reasons their data is so important is that it includes patients with multiple cancers, as well as patients receiving multiple different treatments
.
"The patients themselves are also diverse, and they are also representative of the patients we are treating,
" Halmos said.
"Of these, about 1/3 are black and 40% are Hispanics
.
"

Verma concluded: "The vaccination rate among these groups is low, even if they are hardest hit by the pandemic
.
It is important to understand the use of vaccines in these patient groups
.
" (Source: Chinese Science News Tang Yichen)

Related paper information: http://dx.
doi.
org/10.
1016/j.
ccell.
2021.
06.
002

http://dx.
doi.
org/10.
1016/j.
ccell.
2021.
06.
002 http://dx.
doi.
org/10.
1016/j.
ccell.
2021.
06.
002